Tumor molecular profiling is a fundamental component of precision oncology, enabling the
identification of genomic alterations in genes and pathways that can be targeted …

Background Fusions involving one of three tropomyosin receptor kinases (TRK) occur in
diverse cancers in children and adults. We evaluated the efficacy and safety of larotrectinib, a …

Purpose With prospective clinical sequencing of tumors emerging as a mainstay in cancer
care, an urgent need exists for a clinical support tool that distills the clinical implications …

Background BRAF V600 mutations occur in various nonmelanoma cancers. We undertook
a histology-independent phase 2 “basket” study of vemurafenib in BRAF V600 mutation–…

The AACR Project GENIE is an international data-sharing consortium focused on generating
an evidence base for precision cancer medicine by integrating clinical-grade cancer …

The problem of resistance to therapy in cancer is multifaceted. Here we take a reductionist
approach to define and separate the key determinants of drug resistance, which include …

CD8 + T cell–dependent killing of cancer cells requires efficient presentation of tumor
antigens by human leukocyte antigen class I (HLA-I) molecules. However, the extent to which …

Acquired mutations are pervasive across normal tissues. However, understanding of the
processes that drive transformation of certain clones to cancer is limited. Here we study this …

We integrated the genomic sequencing of 1,918 breast cancers, including 1,501 hormone
receptor-positive tumors, with detailed clinical information and treatment outcomes. In 692 …

Background The selective TRK inhibitor larotrectinib was approved for paediatric and adult
patients with advanced TRK fusion-positive solid tumours based on a primary analysis set of …